KYMR
Kymera Therapeutics Inc.
$51.01
+$1.88(+3.83%)
40
Overall
--
Value
40
Tech
--
Quality
Market Cap
$3.51B
Volume
730.91K
52W Range
$19.45 - $53.27
Target Price
$63.05
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | ||
| Total Revenue | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | -- | -- | -- | $78.6M | $47.1M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $80.3M | $173.4M | $208.1M | $244.1M | $308.7M | ||
| Research & Development | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | ||
| Research Expense | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | ||
| Selling, General & Administrative | $27.3M | $36.3M | $43.8M | $55.0M | $63.5M | ||
| Selling & Marketing Expenses | $9.1M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | ||
| Salaries & Wages | -- | -- | $35.5M | $43.1M | $55.0M | ||
| Depreciation & Amortization | $1.8M | $2.4M | $3.0M | $3.6M | $7.4M | ||
| Depreciation & Amortization | $1.8M | $2.4M | $3.0M | $3.6M | $7.4M | ||
| Amortization | $716.0K | $906.0K | $1.2M | $1.5M | $1.4M | ||
| Other Operating Expenses | $4.2M | $4.2M | $4.7M | $12.5M | $16.7M | ||
| OPERATING INCOME | |||||||
| Operating income | $-46.3M | $-100.5M | $-161.3M | $-165.5M | $-261.6M | ||
| EBITDA | $-43.7M | $-97.6M | $-151.7M | $-143.2M | $-211.3M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $115.0K | $175.0K | $176.0K | $196.0K | $5.2M | ||
| Intinc | -- | -- | -- | $18.8M | $38.0M | ||
| Net Non-Operating Interest Income/Expense | $-121.0K | $-158.0K | $-6.4M | $18.6M | $32.9M | ||
| Other Income/Expense | $-711.0K | $-313.0K | $-6.4M | $-18.6M | $-32.9M | ||
| Other Special Charges | $711.0K | $313.0K | $6.4M | $18.6M | $37.8M | ||
| SPECIAL ITEMS | |||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $4.9M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-45.5M | $-100.0M | $-154.6M | $-146.8M | $-218.7M | ||
| Pre-Tax Income | $-54.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | ||
| NET INCOME | |||||||
| Net Income | $-45.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | ||
| Net Income (Continuing Operations) | $-45.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | ||
| Net Income (Discontinued Operations) | $-45.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | ||
| Net Income (Common Stockholders) | $-54.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | ||
| Normalized Income | -- | -- | -- | -- | $-216.7M | ||
| TOTALS | |||||||
| Total Expenses | $80.3M | $173.4M | $208.1M | $322.7M | $355.8M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $17.3M | $48.0M | $53.9M | $58.4M | $75.0M | ||
| Average Shares Outstanding (Diluted) | $17.3M | -- | $53.9M | $58.4M | $75.0M | ||
| Shares Outstanding | $44.8M | $51.7M | $55.2M | $61.1M | $64.9M | ||
| Basic EPS | $-3.15 | $-2.09 | $-2.87 | $-2.52 | $-2.98 | ||
| Basic EPS (Continuing Operations) | $-3.15 | $-2.09 | $-2.87 | $-2.52 | $-2.98 | ||
| Diluted EPS | $-3.15 | $-2.09 | $-2.87 | $-2.52 | $-2.98 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.87 | $-2.52 | $-2.98 | ||
| OTHER METRICS | |||||||
| Allowances For Construction | $9.1M | -- | -- | -- | -- | ||
| Marketing Expense | $9.1M | -- | -- | -- | -- | ||
| Other Gand A | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYMR | $51.01 | +3.8% | 730.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kymera Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW